Myovant Sciences Price to Free Cash Flow Ratio 2017-2021 | MYOV

Historical price to free cash flow ratio values for Myovant Sciences (MYOV) since 2017. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Myovant Sciences Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-12-03 14.66 3.25
2021-09-30 22.44 $4.50 4.98
2021-06-30 22.77 $2.87 7.94
2021-03-31 20.58 $4.10 5.02
2020-12-31 27.62 $4.83 5.72
2020-09-30 14.05 $-2.30 0.00
2020-06-30 20.62 $-2.58 0.00
2020-03-31 7.55 $-2.59 0.00
2019-12-31 15.52 $-3.11 0.00
2019-09-30 5.20 $-3.26 0.00
2019-06-30 9.05 $-3.53 0.00
2019-03-31 23.87 $-3.37 0.00
2018-12-31 16.41 $-3.13 0.00
2018-09-30 26.55 $-2.75 0.00
2018-06-30 22.87 $-2.24 0.00
2018-03-31 21.27 $-1.98 0.00
2017-12-31 12.64 $-1.63 0.00
2017-09-30 15.47 $-1.26 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.368B $0.059B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90